Retatrutide vs Semaglutide vs Tirzepatide: Receptor Targets & Research Focus

The incretin peptide class at a glance

Incretins are gut-derived hormones that signal through specific cell-surface receptors involved in metabolic regulation. The two most-studied incretin receptors are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide); a third, closely related target, the glucagon receptor, sits in the same signalling family. An agonist is simply a molecule that binds and activates such a receptor — the opposite of an antagonist, which blocks it.

The three peptides on this page belong to that same investigational class, and the cleanest way to tell them apart is by how many of those receptors each one is designed to engage. Semaglutide is described in the literature as a single agonist, tirzepatide as a dual agonist, and retatrutide as a GLP-1 / GIP / glucagon triple agonist. That single-vs-dual-vs-triple framing — the number of receptor targets a molecule was engineered around — is the axis every comparison below returns to. It is a structural description of what each peptide binds, not a statement about what any of them does in a body.

Side-by-side comparison table

The receptor targets, peptide class and published trial programs, side by side. Trial programs are named neutrally as research that has been conducted; no outcome figures, effect sizes or rankings are presented here, because those would be efficacy claims we do not make. Read the table as “what each molecule targets and which programs studied it,” nothing more.

Semaglutide — GLP-1 receptor research

Semaglutide is described in the literature as a single GLP-1 receptor agonist: a peptide engineered to activate one incretin receptor, GLP-1. Because it targets a single receptor, it serves as the reference point against which the dual- and triple-agonist molecules are structurally compared — the baseline case of “one target.”

The published research on semaglutide is extensive and is most often grouped under the STEP clinical-trial program, which examined the molecule in metabolic contexts. For the purposes of this comparison we note only two neutral facts: which receptor it engages (GLP-1), and that a named, published body of trials exists. We deliberately present no trial outcomes, no effect figures and no positioning of semaglutide against the others — this page is about receptor architecture and research focus, and reporting outcomes as a reader-facing result would cross into efficacy claims. Semaglutide is a widely studied single-agonist peptide; the two molecules below build outward from that single-receptor starting point.

Tirzepatide — dual GLP-1/GIP research

Tirzepatide adds a second receptor target, GIP, alongside GLP-1 — which is why the literature describes it as a dual agonist. Structurally, that is the one difference from semaglutide worth holding onto: the added GIP target. GIP is the other principal incretin receptor, so a dual GLP-1/GIP agonist is engineered to engage both arms of the incretin system rather than one.

The research question a dual agonist raises is a mechanistic one — how simultaneously engaging two incretin receptors differs, at the signalling level, from engaging a single receptor. The published SURPASS and SURMOUNT trial programs studied tirzepatide in metabolic models, and we cite them here only by name and as evidence that such research has been conducted. As with semaglutide, no outcomes are reproduced: the comparison is confined to receptor targets (GLP-1 + GIP), peptide class (dual agonist) and the existence of a named research program.

Retatrutide — triple GLP-1/GIP/glucagon research

Retatrutide adds a third receptor, glucagon, to the GLP-1 and GIP targets — making it a triple agonist, the most receptor-complex molecule of the three. The glucagon receptor is a related member of the same signalling family, so a triple agonist is designed to engage all three targets at once. The distinguishing structural fact is simply that added glucagon-receptor activity on top of the dual-agonist profile.

Crucially, retatrutide is investigational. It has been examined in Phase 2 metabolic research — the Jastreboff et al. report in the New England Journal of Medicine (2023) is the most-cited primary source — but it is not an approved medicine and remains under study. Where semaglutide and tirzepatide have large published trial programs behind them, retatrutide sits earlier in the research pipeline. The scientific interest, framed neutrally, is in what a simultaneous three-receptor profile does at the mechanistic level — a research question, not a demonstrated result. You can view the research compounds themselves on the Retatrutide 10 mg and Retatrutide 20 mg pages, and go deeper on the single molecule — receptor pharmacology, molecule properties, and the named trials — in the retatrutide research deep-dive.

How the three differ in research design

Beyond receptor count, the published programs differ in the models and endpoints researchers set out to examine. The through-line is escalating receptor complexity: a single-agonist program (semaglutide) asks what engaging GLP-1 alone does; a dual-agonist program (tirzepatide) asks how adding GIP changes the picture; and a triple-agonist program (retatrutide) adds the glucagon arm and, in the published Phase 2 work, extended the models studied to include hepatic-fat systems alongside the metabolic ones.

The right way to read that progression is as a widening research focus — the set of questions each trial was designed to investigate — not as a ladder of increasing benefit. Each added receptor is a new mechanistic variable to study, which is why the programs grow in scope as targets are added. None of this should be read as a result a reader would obtain, the molecules are not ranked, and this page draws no “which is better” conclusion: a verdict of that kind would be an efficacy claim, which we do not make. What the comparison legitimately supports is a structural map — one, two or three receptors — and a pointer to the named programs where each was studied.

Research-grade sourcing & verification

Whichever molecule a research question concerns, the sourcing standard is the same. Cellworks supplies these compounds for research use only, each with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, plus a lot number you can check yourself on the self-serve verify tool — so the identity and purity of the exact vial in hand are documented rather than assumed. See our quality standards for how each batch is tested and recorded, and browse the metabolic research range on /shop.

FAQ